Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADRO NASDAQ:LXRX NASDAQ:OSMT NASDAQ:SNDX NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADROAduro Biotech$10.93$4.51▼$20.20$236.61M0.4162,237 shs171,500 shsLXRXLexicon Pharmaceuticals$1.40+0.7%$1.27$0.28▼$2.08$505.13M1.232.88 million shs782,296 shsOSMTOsmotica Pharmaceuticals$1.16$0.98▼$4.95$69.47M2.34396,682 shs296,500 shsSNDXSyndax Pharmaceuticals$14.68-2.8%$15.66$8.58▼$22.50$1.30B0.682.48 million shs1.99 million shsWVEWAVE Life Sciences$7.05-1.8%$7.98$5.28▼$16.74$1.14B-1.372.30 million shs2.47 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADROAduro Biotech0.00%0.00%0.00%0.00%0.00%LXRXLexicon Pharmaceuticals+0.72%-4.76%+15.70%+27.27%-24.73%OSMTOsmotica Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SNDXSyndax Pharmaceuticals-2.85%-2.46%-1.14%+52.44%-20.82%WVEWAVE Life Sciences-1.81%-10.42%+3.22%-16.07%-51.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADROAduro Biotech$10.93$4.51▼$20.20$236.61M0.4162,237 shs171,500 shsLXRXLexicon Pharmaceuticals$1.40+0.7%$1.27$0.28▼$2.08$505.13M1.232.88 million shs782,296 shsOSMTOsmotica Pharmaceuticals$1.16$0.98▼$4.95$69.47M2.34396,682 shs296,500 shsSNDXSyndax Pharmaceuticals$14.68-2.8%$15.66$8.58▼$22.50$1.30B0.682.48 million shs1.99 million shsWVEWAVE Life Sciences$7.05-1.8%$7.98$5.28▼$16.74$1.14B-1.372.30 million shs2.47 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADROAduro Biotech0.00%0.00%0.00%0.00%0.00%LXRXLexicon Pharmaceuticals+0.72%-4.76%+15.70%+27.27%-24.73%OSMTOsmotica Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SNDXSyndax Pharmaceuticals-2.85%-2.46%-1.14%+52.44%-20.82%WVEWAVE Life Sciences-1.81%-10.42%+3.22%-16.07%-51.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADROAduro Biotech 0.00N/AN/AN/ALXRXLexicon Pharmaceuticals 2.29Hold$3.23130.36% UpsideOSMTOsmotica Pharmaceuticals 0.00N/AN/AN/ASNDXSyndax Pharmaceuticals 2.91Moderate Buy$38.00158.86% UpsideWVEWAVE Life Sciences 2.85Moderate Buy$21.00197.87% UpsideCurrent Analyst Ratings BreakdownLatest ADRO, WVE, SNDX, OSMT, and LXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$18.0010/16/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.0010/15/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/8/2025LXRXLexicon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025WVEWAVE Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LXRXLexicon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025WVEWAVE Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/19/2025SNDXSyndax PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.009/10/2025SNDXSyndax PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADROAduro Biotech$17.26M0.00N/AN/A$4.07 per share0.00LXRXLexicon Pharmaceuticals$58.43M8.71N/AN/A$0.40 per share3.50OSMTOsmotica Pharmaceuticals$177.88M0.00N/A1.00$1.50 per share0.00SNDXSyndax Pharmaceuticals$23.68M53.40N/AN/A$3.38 per share4.34WVEWAVE Life Sciences$108.30M10.36N/AN/A$1.37 per share5.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADROAduro Biotech-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/ALXRXLexicon Pharmaceuticals-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%11/11/2025 (Estimated)OSMTOsmotica Pharmaceuticals-$79.59M-$1.59N/AN/AN/A-138.76%-81.23%-20.97%N/ASNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest ADRO, WVE, SNDX, OSMT, and LXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025LXRXLexicon Pharmaceuticals-$0.07N/AN/AN/A$5.81 millionN/A11/11/2025Q3 2025WVEWAVE Life Sciences-$0.30N/AN/AN/A$9.85 millionN/A11/4/2025Q3 2025SNDXSyndax Pharmaceuticals-$0.73N/AN/AN/A$49.08 millionN/A8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.08$0.01+$0.09$0.01$4.87 million$28.87 million8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADROAduro BiotechN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AOSMTOsmotica PharmaceuticalsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADROAduro BiotechN/A8.918.91LXRXLexicon Pharmaceuticals0.434.164.16OSMTOsmotica PharmaceuticalsN/A0.430.42SNDXSyndax Pharmaceuticals2.064.714.55WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADROAduro Biotech49.93%LXRXLexicon Pharmaceuticals74.70%OSMTOsmotica Pharmaceuticals46.18%SNDXSyndax PharmaceuticalsN/AWVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipADROAduro Biotech5.90%LXRXLexicon Pharmaceuticals13.90%OSMTOsmotica Pharmaceuticals5.22%SNDXSyndax Pharmaceuticals4.10%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADROAduro Biotech15216.21 millionN/AOptionableLXRXLexicon Pharmaceuticals140363.40 million312.89 millionOptionableOSMTOsmotica Pharmaceuticals30262.59 million59.32 millionNot OptionableSNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableADRO, WVE, SNDX, OSMT, and LXRX HeadlinesRecent News About These CompaniesWAVE Life Sciences (NASDAQ:WVE) Trading Down 11.4% - Here's WhyOctober 23 at 4:32 PM | marketbeat.comWave Life Sciences management to meet with TruistOctober 21 at 7:56 PM | msn.comWAVE Life Sciences (NASDAQ:WVE) Coverage Initiated at Wells Fargo & CompanyOctober 20, 2025 | marketbeat.comClear Street Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationOctober 16, 2025 | msn.comWave Life Sciences initiated with a Buy at Clear StreetOctober 14, 2025 | msn.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Rating of "Moderate Buy" from AnalystsOctober 14, 2025 | americanbankingnews.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 14, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Stock Price Down 5.3% - Here's What HappenedOctober 11, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading Up 9.3% - Should You Buy?October 10, 2025 | marketbeat.comWave Life Sciences (WVE): A Valuation Deep Dive Following Pipeline Progress and Investor OptimismOctober 10, 2025 | finance.yahoo.comStrength Seen in Wave Life Sciences (WVE): Can Its 11.4% Jump Turn into More Strength?October 10, 2025 | zacks.comWAVE Life Sciences' (WVE) "Sell (D-)" Rating Reaffirmed at Weiss RatingsOctober 8, 2025 | marketbeat.comWave Life Sciences (WVE) Receives a Buy from Leerink PartnersOctober 7, 2025 | theglobeandmail.comCanaccord Genuity Keeps Their Buy Rating on Wave Life Sciences (WVE)October 7, 2025 | theglobeandmail.comWAVE Life Sciences Ltd. $WVE Stake Raised by Platinum Investment Management Ltd.October 2, 2025 | marketbeat.comInvivyd appoints Wave Life Sciences CEO Paul Bolno to boardSeptember 25, 2025 | msn.comWave Life Sciences Highlights WVE-007 Obesity TreatmentSeptember 25, 2025 | msn.com3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025September 18, 2025 | zacks.comWave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor ConferencesSeptember 18, 2025 | globenewswire.comWave Life Sciences (WVE) Sees Promising Results From RestorAATion-2 StudySeptember 10, 2025 | finance.yahoo.comRaymond James Reaffirms Their Buy Rating on Wave Life Sciences (WVE)September 9, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADRO, WVE, SNDX, OSMT, and LXRX Company DescriptionsAduro Biotech NASDAQ:ADROChinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.Lexicon Pharmaceuticals NASDAQ:LXRX$1.40 +0.01 (+0.72%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$1.41 +0.01 (+0.71%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Osmotica Pharmaceuticals NASDAQ:OSMTOsmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.Syndax Pharmaceuticals NASDAQ:SNDX$14.68 -0.43 (-2.85%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$15.02 +0.34 (+2.28%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.WAVE Life Sciences NASDAQ:WVE$7.05 -0.13 (-1.81%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$7.22 +0.17 (+2.40%) As of 08:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
